Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Accelerated sequential epirubicin followed by intravenous CMF with pegfilgrastim in early breast cancer
ISRCTN07812773Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Mar 2005
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of epirubicin, cyclophosphamide, methotrexate, fluorouracil, pegfilgrastim and 1 more in breast cancer, sponsored by University of Birmingham. Primary endpoint: Delivered dose intensity. Started Mar 2005; status: completed.
02
Drugs
epirubicincyclophosphamidemethotrexatefluorouracilpegfilgrastim
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN07812773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN07812773.